0000899243-19-023912.txt : 20190919
0000899243-19-023912.hdr.sgml : 20190919
20190919160527
ACCESSION NUMBER: 0000899243-19-023912
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190917
FILED AS OF DATE: 20190919
DATE AS OF CHANGE: 20190919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ENRIGHT PATRICK G
CENTRAL INDEX KEY: 0001253886
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 191101819
MAIL ADDRESS:
STREET 1: CO LONGITUDE CAPITAL PARTNERS LLC
STREET 2: 800 EL CAMINO REAL, SUITE 220
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-17
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001253886
ENRIGHT PATRICK G
C/O LONGITUDE CAPITAL PARTNERS II, LLC
2740 SAND HILL ROAD, SECOND FLOOR
MENLO PARK
CA
94025
1
0
0
0
Common Stock, $0.0001 par value
2019-09-17
4
A
0
12500
22.3373
A
45561
D
Common Stock, $0.0001 par value
6013134
I
By: LVP2
The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $22.28 to $22.42 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
Reflects shares held by Longitude Venture Partners II, L.P. ("LVP2"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. Patrick G. Enright is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LVP2. Mr. Enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
/s/ Douglas T. Sheehy, as Attorney-in-Fact for Patrick G. Enright
2019-09-19